Alnylam Pharmaceuticals (ALNY) Slumps as Researchers Raise Red Flags
- Stocks Tank as QE Nears End, Major Fund Winds Down, and Ebola Fears
- Market Wrap: Private Employment Expands in Sept.; BofA CEO Becomes Chairman; U.S. Secret Service Director Resigns
- Bank of America (BAC) CEO Moynihan Elected as Chairman
- After-Hours Stock Movers 10/01: (RLD) (DRL) (DTV) Higher; (WILN) (NLNK) (PLTA) Lower (more...)
- Investors Yank $23.5 Billion From PIMCO in 3 Days Amid Gross Exit
Shares of Alnylam Pharmaceuticals (Nasdaq: ALNY) slumped on Thursday. Traders say the stock's decline could relate to questions raised about treatments targeting alpha-synuclein. According to reports, drugs aimed at alpha-synuclein could be making people worse. Questions raise concerns about patients in clinical trials to lower alpha-synuclein.
You May Also Be Interested In
- UPDATE: Yahoo! (YHOO) Active on Chatter
- Computer Sciences Corp. (CSC): DealReporter Says LBO Unlikely
- UPDATE: Apache Corporation (APA) May Sell Oil, Gas Assets in Texas and Oklahoma - Reuters
Create E-mail Alert Related CategoriesFDA, Rumors, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!